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The leukocyte common (LC) 1 antigen, originally described in the rat using conven- 
tional absorbed rabbit anti-rat lymphocyte sera (1), and later in the rat (2) and mouse 
(where it  was termed T200)  (3) using monoclonal antibodies, is a  well characterized 
and  major  glycoprotein of the  rodent  lymphocyte surface.  It  is  widely  distributed 
among leukocytes, being found on T  and B lymphocytes, thymocytes, macrophages, 
and granulocytes, but is absent from other tissues (1-3). An interesting feature of this 
molecule is that its mobility on sodium dodecyl sulfate (SDS) gels varies, depending 
on the cell type being studied. Thus, the LC antigens of rat thymocytes, T  lympho- 
cytes, and  B  lymphocytes migrate on  SDS  gels with  apparent  mol  wt  of 150,000, 
170,000, and 200,000, respectively (2); whereas in the mouse, LC antigens from T  and 
B lymphocytes have tool wt of 190,000 and 220,000, respectively (3). These differences 
in  mobility of the molecule on functionally different cell  populations are extremely 
interesting, and the structural basis for the differences are at the moment completely 
unknown. 
We have recently characterized the human homologue of the rodent LC antigen 
(4) with a  monoclonal antibody. The human LC antigen is very similar to the rodent 
homologue,  being  found  on  T  and  B  lymphocytes,  thymocytes,  monocytes,  and 
granulocytes, but  absent  from other tissues;  and  it  is  a  major, lentil-lectin-binding 
glycoprotein of the human lymphocyte. When purified from blood lymphocytes, two 
peaks are seen, one at  190,000  and the other at 215,000 tool wt, which are probably 
the LC antigen from T  and B lymphocytes, respectively (4). 
In this paper we demonstrate that  in addition  to the determinant  common to all 
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human LC molecules, a subset of LC molecules express a  new determinant, and that 
this new determinant is selectively expressed  principally on the  LC  molecules of B 
lymphocytes.  This  selective  expression,  on  a  functionally discrete  population  of 
lymphocytes, of a serologically identifiable conformational or other structural change 
has  interesting implications for the  function(s) of the  LC  molecules. The data also 
forcefully illustrate how the target  of monoclonal antibodies must be considered at 
the determinant rather than the molecular level. 
Materials and Methods 
Cell Suspensions.  Except for the target cells in the binding assay,  all cell suspensions were 
prepared fresh  immediately before use, and for most experiments were in 0.5% bovine serum 
albumin (BSA)  (Miles Laboratories,  Stoke  Poges,  Slough,  England)  in phosphate-buffered 
saline (PBS)  (Dulbecco's A and B; Oxoid Ltd., London). Spleen was taken from splenectomy 
cases  for  trauma or from  cadaver kidney donors, and cervical lymph nodes were  taken at 
surgery from  patients without  systemic illness.  Thymus was  taken  as  1-cm  3 biopsies from 
prepubertal patients at open heart surgery. Bone marrow came from ribs removed at tboracot- 
omy. Granulocytes were prepared from EDTA anti-coagulated blood as described by B/~yum 
(5), and peripheral blood mononuclear cells (PBL)  were prepared from defibrinated blood by 
centrifuging over Lymphoprep (Nyegaard, Oslo, Norway). Rat lymph nodes were a mixture of 
cervical and  mesenteric nodes  obtained from  freshly  exsanguinated DA  rats  (Bantin and 
Kingman Ltd.,  Aldbrough, Hull, Yorkshire,  England). Contaminating erythrocytes  (RBC) 
were removed from all cell suspensions except bone marrow by incubating with Tris-buffered 
ammonium chloride (6). Viability was assessed by trypan blue exclusion and was almost always 
>80%.  Relatively pure RBC suspensions were obtained from heparinized blood by washing 
three times and removing supernate, buffy coat, and upper RBC layer after each wash.  Cell 
counts were performed by using a model DN Coulter Counter (Coulter Electronics, London). 
Pure suspensions of platelets were prepared  by removing leukocytes and RBC from  EDTA 
anti-coagulated blood by two sequential spins at 200 g for 20 rain. Platelets were washed twice 
by centrifugation and counted under phase-contrast microscopy on a hemocytometer. 
The  targets  in  the  binding assays  were  human  spleen  cells  fixed  for  5  rain  in  0.25% 
glutaraldehyde and stored at -40°C in 5% BSA/PBS (7). 
Tissue Homogenates.  Liver,  heart,  and  kidney were  obtained  fresh  from  cadaver  kidney 
donors and a piece of cerebrum was obtained fresh from the Neurosurgery Unit, John Radcliffe 
Hospital, Oxford, England. The capsule of the organ to be homogenized was removed and the 
tissue minced in PBS using mechanically  driven blades, followed by mechanical homogenization 
with  a  Teflon pestle  and  then  manual ground-glass homogenization. Large  particles  were 
removed by centrifuging at 40 g for 1 min. The homogenate was washed twice by centrifuging 
at 35,000 g for 20 min. The second pellet was resuspended by manual ground-glass homogeni- 
zation, aliquoted, and stored at -40°C. All procedures were carried out at 4°C or on ice. The 
protein content of the homogenates was estimated by the method of Lowry et al. (8) using BSA 
as a standard. 
Antibodies.  Immunoadsorbent-purified  rabbit F(ab')2 anti-mouse F(ab')2 (RAM) and rabbit 
F(ab')z anti-human F(ab')~ (RAH) were  prepared as previously described for other immuno- 
adsorbent-purified anti-immunoglobulin  sera  (9). The pepsin degradation of the mouse and 
human immunoglobulins  was carried out at pH of 4.1 and 4.5, respectively. 
The antibodies were iodinated using the chloramine T method and fluorescein labeled using 
bicarbonate buffer, pH 9.5, for 3 h at room temperature, as previously described in detail (10). 
With the  fluorescence-activated cell  sorter  (B-D  FACS Systems,  Mountain View,  Calif.), 
cross-reactivity between mouse and human immunoglobulins  resulted in unacceptably high 
backgrounds where B lymphocytes were present in the cell population under study. This was 
overcome by passing the fluorescein-labeled RAM through a  10-ml Sepharose 4B (Pharmacia, 
Uppsalla, Sweden) column to which had been coupled 10 mg of human F(ab')z/ml of gel. 
Binding  Assay.  Binding assays  were  performed  essentially as  described  by  Morris  and 
Williams (11). All procedures were at 4°C or on ice. Duplicate 25-/zl samples of immune ascites 
or culture supernate to be assayed  were transferred to LP3 tubes (Luckham Ltd., Burgess Hill, ROSEMARIE  DALCHAU AND JOHN  W.  FABRE  755 
Sussex, England). If the samples to be assayed had been used in absorption analysis, they were 
centrifuged at 6,000 g for 5 min immediately before assay. 25 p.l of glutaraldehyde-fixed spleen 
cell targets at 10S/ml were then added to each tube and this was incubated for 1 h on ice. The 
cells were then washed twice in 0.1% BSA/PBS and 100 ~l of ~25I-labeled RAM in 0.5% BSA/ 
PBS (~300,000 cpm/tube) was added to the pellet of the second wash. This was resuspended, 
incubated for a further 1 h on ice, and the cells washed twice as above. The pellet of the second 
wash was  resuspended in 0.5  ml of PBS,  transferred to fresh  LP3 tubes, and the target cell- 
bound radioactivity measured in a  Packard gamma counter (Packard Instrument Co., Inc., 
Downers Grove, Ill.). 
Absorption Analysis.  Initial titrations of immune ascites or culture supernate were performed 
to choose a  dilution that represented conditions of target antigen excess in the assay system. 
Absorptions were  then performed  at  this dilution by incubating equal  volumes (80 btl) of 
antibody  sample at the chosen dilution  with tripling dilut  ions of homogenates or cell suspensions 
in 0.5% BSA/PBS. Again, all procedures were at 4°C or on ice. Absorbing tissue was removed 
by  eentrifugation and  absorbed  samples  stored  at  -40oC  until all  the  absorptions  for  a 
particular analysis had been completed. 
For the absorptions, homogenates were used at starting concentrations as prepared above: 
i.e., 50% solid tissue,  which corresponded to 25-35 mg homogenate protein/ml. Alignment of 
absorption curves for different homogenates was done on the basis of protein content. Cell 
suspensions were used at starting concentrations of 109/ml. 
Production of Monoclonal Antibodies.  This was performed essentially as previously described by 
Kibhler and Milstein (12), and the details of the technique used in this laboratory have been 
published previously (4). 
Mice were  immunized with  fresh  human lymph node lymphoeytes depleted of surfaee- 
immunoglobulin-positive  cells. The depletion was done by rosetting the lymph node lympho- 
cytes with human RBC to which RAH had been coupled using the CrC13 method (13) and 
then centrifuging over Lymphoprep of specific gravity 1.077. BALB/c mice were then injected 
intravenously with 107 cells on three occasions, the third injection being 5 d before the fusion. 
Fusions were carried out with the myeloma P3-NS1/1Ag 4.1  (NS-1), kindly provided by Dr. 
G. Milstein (MRC Laboratory of Molecular Biology, Cambridge, England). Immunized mice 
were killed by cervical dislocation and a single cell suspension prepared from their spleens. This 
was mixed with NS-1 eel}s in the ratio of I0 nucleated spleen cells: t myeloma cell, and the cells 
fused using polyethylene glycol, Hybrids were selected in hypoxanthine-aminopterin-thymidine 
medium. The culture conditions, cloning procedures by dilution, and production of immune 
ascites were by standard techniques (4). 
For partial purification of the monoclonaI antibody, aseites  was  pooled, dialyzed against 
0.15 M NaC1, 0.025 M Tris, 0,02%, sodium azide, pH 8.5, at 4°C, and passed through DEAE- 
CL 6B (Pharmacia) previously equilibriated with the above buffer. The monoclonal antibody 
activity passed unretarded through the column, and all antibody activity was recovered with 
~ 15% of the ascites  protein. 
Monoclonal Antibody Affinity  Chromatography.  Pilot experiments titrating antigen activity of 
different detergent extracts of spleen homogenate established that  Brij  96  (Sigma Chemical 
Co., London) gave the best results.  Extracts with 2%  Brij  96 contained the antigen in good 
yield (-50%) and antigen activity remained in the supernate after centrifugation at 85,000 g 
for  75  min. As  previously described, 2%  Brij  96  also solubilized the  LC  antigen (4). Bulk 
extraction of antigen from spleen homogenate was  done by incubating the homogenate at a 
concentration of 10% solid tissue in 2% Brij 96 in 0.15  M  NaC1, 0,025  M Tris, 0.02% sodium 
azide, pH 7.5, at 5°C for 1 h on ice, and centrifuging at  1,500  g for  15 rain to remove nuclei. 
In some experiments OH-labeled antigen was prepared from lymph node lymphocytes. For 
these studies, lymph node lymphocytes depleted of RBC  were  labeled with  NaB[all4]  (14). 
Briefly,  1 ×  108-2 ×  l0  s lymphocytes were incubated on ice for 5 min at 2.5 ×  107/ml in 1 mM 
NalO4 in PBS_ The reaction was stopped by adding 0.1 volume of 0.1 M glsYeerol  , and the cells 
were washed three times in PBS at 4°C. They were resuspended to 1 X  10/ml in PBS, and 1 
mCi (40 pl) of NaB[all4]  (Radiochemical Centre, Amersham, England) in 0.01 M  NaOH was 
added per t0  s lymphocytes. This was incubated for 30 rain at room temperature, and the cells 
washed three times at 4°C. After the third wash, the cells were resuspended at  10S/ml in 2% 756  B-SPECIFIC  DETERMINANT OF HUMAN  LEUKOCYTE  COMMON  ANTIGEN 
Brij  96  in  PBS  that  contained  2.5  mM  iodoacetamide and  2  mM  phenylmethylsuiphonyl 
fluoride for inhibition of proteolysis (all chemicals from Sigma Chemical Co.). After 30 min on 
ice, this was centrifuged at  1,500 g for 15 rain to remove nuclei. More than 90% of the counts 
were recovered in the supernate, which was immediately frozen at -80°C. Approximately 1.5- 
2.0 X  106 cpm were recovered per l0  s starting cells. 
Monoclonal antibody affinity columns were  prepared by coupling the partially purified 
monoclonal antibody to cyanogen bromide-activated Sepharose 4B (Pharmacia) essentially as 
recommended by the manufacturers.  Coupling was done at a  ratio of 5 mg protein: 1 ml of 
swollen gel. The columns consisted of 0.7 ml of gel in 2-ml glass syringes. 10 ml Brij extracts of 
spleen homogenate or 1 ml Brij extracts of 3H-lymph node lymphocytes (containing ~ 106 cpm) 
was passed through the columns at 5 and 2 ml/h, respectively. The columns were then washed 
with  10-20 ml of 0.5%  Brij 96 in 0.15  M  NaCI, 0.025  M  Tris, 0.02%  NaNs, pH 7.5, at 5°(3. 
Unlabeled antigen was eluted with 0.05 M  diethylamine, 0.5%  Brij 96, pH  11.5, at 5°(3, and 
eluted fractions were immediately neutralized with solid glycine. With this system, all antigen 
activity was recovered in the elution volume of 0.3-1 ml. With the SH-labeled samples, better 
elution was obtained by removing the beads from the column, adding an equal volume of 4% 
SDS, and placing in a boiling water bath for 2 rain. 
Polyac~ylamide Gel Electrophoresis (PAGE) in SDS.  The technique for PAGE-SDS was essen- 
tially as described by Laemmli (15), using 3-mm thick 5% polyacrylamide analytical gels with 
3% polyacrylamide stacking gels (Bio-Rad Laboratories, Richmond, (3alif.). At the completion 
of electrophoresis, the portion of the gel containing the molecular weight standards (Bio-Rad 
Laboratories) was cut from the main part of the gel and stained with Coomassie blue. The 
remainder of the gel was cut  into strips corresponding to the samples analyzed, and  fixed 
overnight in methanol/acetic acid. 2-ram thick slices were then cut, placed into counting vials, 
and  0.6  ml  of nuclear Chicago solubilizer (NCS;  Hopkins  and  Williams, Romford,  Essex, 
England)  was  added.  This  was  incubated  at  50°(2  for  2  h  and  then  overnight  at  room 
temperature.  2  ml  of scintillant  was  then  added,  and  the  samples counted  in  a  Packard 
scintillation counter. 
Fluorescence-activated Cell Sorter (FACS).  Immune ascites was always used for FA(3S analysis 
and a dilution was chosen which represented conditions of antibody excess. This dilution was 
chosen  by performing saturating binding assays, where  the second incubation of the  assay 
contained 25 #g/ml of unlabeled RAM in addition to the 12SI-RAM (11). Cells were prepared 
in binding assays as described above; the second incubation was with fluorescein-labeled RAM 
or RAH at the saturating concentration (11) of 25/tg/ml, and in some experiments, both RAM 
and RAH together. As a control monoclonal antibody, a monoclonal anti-dog Thy-1 (16) was 
used. The control for RAH was RAH blocked with 250 #g/ml of human F(ab')2 for 1 h at 4°C. 
Results 
Tissue Distribution  of the F8-11-13 Determinant 
QUANTITATIVE ABSORPTION ANALYSIS.  The results of absorptions with various tissue 
homogenates  are given in Fig.  1, and  it is clear that  kidney, liver, heart,  and  brain 
give little or no absorption, so the determinant recognized by the FS- 11-13 antibody 
is specific to leukocytes. Fig. 2 shows that single cell suspensions of spleen and lymph 
node lymphoeytes have large and approximately equal amounts of F8-11-13, whereas 
bone  marrow  and  thymus  have  ~30  and  10%  as much,  respectively, as spleen  and 
lymph node. Granulocytes, as well as platelets, erythrocytes, and serum, do not absorb 
the antibody. The  major difference with previous studies of the LC antigen  is that 
granulocytes gave excellent absorption for the LC antigen (4). 
FACS  ANALYSIS.  To  better  characterize  the  F8-11-13  determinant  in  leukocyte 
populations,  thymocytes,  bone  marrow  cells,  granulocytes,  PBL,  and  lymph  node 
lymphocytes, each from several individuals, were studied on the FACS. The results of 
typical FACS analyses with each tissue are given in Fig. 3, and the percentage of FS- ROSEMARIE DALCHAU AND JOHN W.  FABRE  757 
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FIG.  2.  Quantitative absorption analysis of FS-1 l-13-immune ascites. Immune ascites at a  1:5,000 
dilution was absorbed with tripling dilutions of normal serum, I-I, and the following cell suspensions: 
spleen, A;  lymph node, m;  bone marrow,  X;  thymus, &;  granulocytes, O;  erythrocytes, "A'; and 
9  platelets, 0. The starting concentration of cells was 10/ml except for platelets, which were used at 
an initial concentration of 6  X  10a/ml and plotted such that six platelets were equivalent to one 
lymphocyte. Normal serum was arbitrarily plotted such that  undiluted serum was equivalent to 
cells at  109/ml. Residual antibody was assayed as in Fig. h 
11-13-positive cells in the tissues studied is given in Table I. It should be noted that 
with  the  F10-89-4  antibody,  which  is  directed  at  the  common determinant  of the 
human LC antigen,  100%  of thymocytes, granulocytes, PBL, and lymph node  (LN) 
lymphocytes,  and  83%  of bone  marrow  cells  are  positive  (4).  With  the  F8-11-13 
antibody,  only a  small  proportion  of thymocytes was positive, and  even  then  only 
weakly so (Fig.  3a), whereas granulocytes were completely negative. With  PBL and 758  B-SPECIFIC  DETERMINANT OF  HUMAN  LEUKOCYTE COMMON  ANTIGEN 
LN  lymphocytes,  only  ~50%  of the cells were  F8-11-13  positive.  PBL  had  a  broad, 
positive  peak  and  appeared  to  be  the  most  strongly  labeled  cell population  studied 
(Fig.  3d),  whereas  LN  lymphocytes  had  a  strongly  staining  peak,  with  a  group  of 
more weakly staining cells to the left of this main peak  (Fig.  3 e). 
Given  that  subpopulations  of PBL  and  LN  lymphocytes  were  being  labeled,  an 
obvious  question  was  to  ask was  whether  or not  the F8-11-13-positive  cells could  be 
designated  as being in  the  B  or T  lymphocyte lineage.  Double-labeling experiments 
were  therefore  performed  on  LN  lymphocytes  using  the  F8-11-13  antibody  and 
fluorescein-labeled  RAM  in  combination  with  fluorescein-labeled  RAH  to  label the 
B  lymphocytes.  The  results are given in Table  II, and  show that  most, but not all, of 
the  B  lymphocytes  (defined  as  immunoglobulin-positive  cells)  are  F8-11-13  positive. 
Most of the surface-immunoglobulin-negative  (presumably  T)  lymphocytes were F8- 
11-13  negative,  and  in  two  of the  three  persons  studied,  the  number  of F8-11-13- 
positive T  lymphocytes was very small. 
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Fla.  3.  FACS analysis  of F8-11-13-immune  ascites  on various cell populations.  Immune ascites 
was used at a  1:500 dilution and tested on (a) thymus; (b) bone marrow; (c) granulocytes; (d) PBL; 
and (e) LN lymphocytes.  In (a), (b), and (d) the faint profile to the left represents  the fluorescence 
profile with an  irrelevant monoclonal antibody.  The marker,  m,  represents  the channel  beyond 
which 0.5,  1.9, 0.7, 0.7, and 0.9% of cells in (a), (b), (c), (d), and (e), respectively, were labeled with 
an irrelevant monoclonal antibody• 
TABLE  I 
FACS Analysis of Various Cell Populations with the F8-11-13 Monoclonal 
Antibody 
Cell type  (Percentage)  F8-11-13-  Mean +  SD 
positive cells* 
Thymocytes  4.8, 5.9, 6.0, 7.6  6.1 +  1.2 
Bone marrow cells  9.9,~ 19.4, 25.7, 32.9  22.0 ±  9.8 
Granulocytes  0, 0 
PBL  37.0, 54.7, 58.4, 60.0  52.5 +  10.6 
LN lymphocytes  36.5, 48.9, 58.5  48.0 +  11.0 
* Each figure represents  a different individual. 
:~ This sample of bone marrow came from an adult, and the other three from 
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TABLE  II 
Double Labehng Experiments to Determine by FAGS Analysis the Overlap between F8-11-13-positive  and 
Surface-Immunogtobulin-positive LN Lymphocytes 
Percentage LN 
Percentage LN  cells positive us-  Percentage of B  Percentage ofT 
Individual  cells positive  Percentagecells  positiveLN  ofingF8-1c°mbinati°nl-13,  and  lymph°cytesll  lymph°eytesll 
with FS-11-13  with fluorescein-  fluorescein-la-  which are FS-  which are FS-  number  and fluorescein- 
labeled RAM*  labeled RAH:~  beled RAM and  11-13  positive  11-13 positive 
RAH§ 
1  36.5  28.7  37.3  97.2  21.1 
2  48.9  45.l  52.6  91.8  13.7 
3  58.5  37.2  63.5  86.8  41.9 
* First incubation with F8-11-13 antibody, second incubation with fluorescein-labeled  RAM. 
:[: First incubation with medium, second incubation with fluorescein-labeled  RAH. 
§ First  incubation with F8-11-13 antibody, second  incubation with a mixture of fluorescein-labeled  RAM 
and RAH. 
II B and T  lymphocytes of lymph node defined as surface-immunoglobulin-positive and  -negative cells, 
respectively. 
~m  b 
FIG. 4.  FACS analysis  with  F8-11-t3-immune ascites  on separated T  and  B tymphocytes from 
LN. Immune aseites was used at a  1:500 dilution and tested on (a) purified B lymphocytes and (b) 
purified T lymphocytes from LN. LN lymphocytes from the same individual were divided into two 
aliquots, and B cells prepared from one aliquot by rosetting with papainized sheep RBC and T cells 
prepared from the other aliquot by rosetting with human RBC to which RAH had been coupled, 
as outlined  in  Materials and  Methods.  The purity of the B and  T  cells was  checked  by  FAGS 
analysis using fluorescein-labeled  RAH, and the B and T cell populations were found to contain of 
91  and 6% Ig-positive cells, respectively.  The marker m, represents  in (a) the point beyond which 
93% of the cells were positive with the F8-11-13 antibody and 0.9% were positive with an irrelevant 
monoclonal antibody and in (b), the point beyond which 33% of the cells were positive with the F8- 
11-13 antibody and 0.6% were positive with the irrelevant monoclonal antibody. 
Two  lines  of evidence  suggest  that  B  lymphocytes  express  quantitatively  much 
more of F8-11-13  determinant  than  T  lymphocytes.  First,  the T  and  B  lymphocytes 
from the LN of individual 2 of Table II were separated  and studied for the expression 
of the  F8-11-13  determinant  on  FACS  analysis,  and  the  results  are  given  in  Fig.  4. 
Fig. 4 b  shows that  the F8-11-13-positive T  lymphocytes express the determinant  only 
weakly,  much  like  thymus  cells  (Fig.  3a).  The  B  lymphocytes,  however  (Fig.  4a), 
express  the  determinant  strongly.  The  second  line  of evidence  is  that  fluorescence 
studies  (performed  as  in  [4])  on  frozen  sections  of LN  from  three  different  persons 
show  that  the  F8-11-13  antibody  stains  predominantly  the  lymphatic  nodules  and 
germinal  centers.  It  is  interesting  that  with  the  monoclonal  antibody  (F10-89-4) 
detecting the determinant  common  to all LC  molecules, we have shown  that  T  cells 
stain  more strongly than  B  cells (4). 
Thus  the  F8-11-13  determinant  is  not  entirely  restricted  to  the  B  lymphocyte 
lineage, but most B  and only some T  cells express it, and B  cell express much  more of 
the determinant  than  do the FS-11-13-positive T  cells. The  relatively strong staining 
of PBL  with  the  F8-11-13  antibody  (Fig.  3 d)  raises  the  possibility  that  monocytes 760  B-SPECIFIC  DETERMINANT  OF  HUMAN  LEUKOCYTE  COMMON  ANTIGEN 
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FI6. 5.  SDS-PAGE analysis of 3H-labeled membrane sialoglycoproteins. LN lymphocytes were 
treated with periodate, labeled with NaB[3H4],  and solubilized with Brij 96 as outlined in Materials 
and Methods. Samples were run on 5% polyacrylamide gels in SDS, and the gels were sliced, and 
the radioactivity measured  in  each  slice.  (a-c)  experiments with  FS-11-13  monoclonal antibody 
columns; (d-f) experiments with F10-89-4 (anti-LC [4]) monoclonal antibody columns. (a) and (d) 
represent  the  solubilized  membrane  before  passage  through  the  affinity  columns;  (b)  and  (e) 
represent the solubilized membrane after passage through the affinity columns; and  (c)  and  (f) 
represent the material that was eluted from the columns. The number ofcpm added to the gels for 
(a),  (b), and (c) were 1.8 ×  l0  s, 8 ×  104, and 1.4 ×  104, respectively, whereas for (d), (e), and (f) the 
cpm added were 1.8 ×  10  ~, 6.4 ×  104, and 2.1  ×  104, respectively. Marker proteins were (molecular 
weights in  parentheses): A,  myosin  (200,000);  B, /~ galactosidase  (130,000);  C,  phosphorylase B 
(94,000);  D, BSA (68,000);  E, ovalbumin (43,000);  and F, dye front. 
and/or  null  cells might also express the determinant  strongly, and  this is currently 
under study. 
Biochemical Characterization of F8-11-13-bearing Molecule.  3H-labeled, detergent-solu- 
bilized  LN lymphocyte membranes were passed through  FS-11-13 monoclonal anti- 
body affinity columns  and  the  bound  antigen  eluted.  The starting membrane, the 
membrane depleted of FS-11-13,  and the eluted  FS-11-13 antigen were analyzed on 
SDS-PAGE.  For  comparison,  the  same  starting  material  was  passed  through  a 
monoclonal antibody (F10-89-4) affinity column directed at the LC antigen, and the 
results are given in Fig. 5. 
If one looks first at the results with the F8-1 I-13 column  (Fig.  5 a-c), one can see 
that  the  starting membrane shows  the  three  major peaks seen  previously with  3H- ROSEMARIE  DALCHAU  AND JOHN  W.  FABRE  761 
labeled PBL (4). These are: (a) a broad band in the 170,000-  to 220,000-mol wt region 
representing the LC antigen  (4);  (b) an unidentified large peak at  120,000 tool wt; 
and  (c) the F10-44-2 antigen  (possibly homologous to the W3/13 antigen of the rat 
[17])  at  the  105,000-tool  wt  region  (18).  The  first  peak  of the  LC  antigen  at  the 
215,000-mol wt region is depleted by the FS-I 1-13 column (Fig. 5b) and can be eluted 
from the column (Fig. 5 c). These data establish that the molecule bearing the F8-11- 
13 determinant is a glycoprotein of 215,000-mol wt, and strongly suggest that the F8- 
11-13  determinant  is  borne  by  the  large  molecular weight  component  of the  LC 
antigen. This is reinforced by showing, in Fig. 5 d-f, the corresponding experiments 
with the monoclonal antibody F10-89-4 affinity column directed at the LC antigen 
(4). Strict specificity of the affinity columns was established by showing that another 
monoclonal antibody (F10-44-2) affinity column depletes the peak at  105,000 tool wt, 
leaving the LC peaks untouched (18). 
Serological Proof That  the F8-11-13  Determinant  Is  Borne by  the  LC Antigen.  On  the 
basis of the biochemical data presented in Fig. 5, we hypothesized that the LC antigen 
on all leukocytes bears a common determinant recognized by the F10-89-4 antibody 
(4) but that there is an additional determinant, restricted largely to B lymphocytes, 
which is recognized by the F8-11-13 antibody. If this hypothesis is correct, one would 
expect that  the material  purified  from the  F8-I1-13 affinity column would  inhibit 
both the F8-11-13 and F10-89-4 antibodies, but  that solubilized spleen depleted of 
F8-11-13-bearing molecules should  inhibit  F10-89-4 and  not  F8-11-13  antibody.  In 
addition, one would expect that the solubilized spleen depleted of F10-89-4 antigen 
would inhibit neither the F8-11-13 nor the F 10-89-4 antibodies, and, conversely, that 
purified  F10-89-4  antigen  would  inhibit  both  antibodies.  As  the  F10-89-4  antigen 
could not be eluted in good yield without denaturation, this last possibility was not 
examined, but the other three were studied and the results are given in Fig. 6. Fig. 6 A 
shows that the F8-11-13 antibody was inhibited by the starting spleen extract and the 
purified F8-11-13 antigen, but not by the spleen extract depleted by passage through 
the  F8-11-13  or F10-89-4 columns.  Fig.  6B  shows  that  the  F10-89-4  antibody was 
inhibited by the starting spleen extract, by the purified F8-11-13 antigen, and also by 
the extract depleted by passage through the F8-11-13 column, but not by the extract 
depleted by passage through the F10-89-4 column. Fig. 6C shows control inhibitions 
of the  F10-44-2  antibody  (18)  discussed  above,  and  shows,  as  expected,  that  the 
starting spleen extract and the extracts depleted by passage through F10-89-4 and F8- 
t 1-13 columns did inhibit, and that the purified F8-11-13 antigen did not inhibit at 
all.  It  is  clear,  therefore, that  the  molecule bearing  the  F8-11-13  determinant  also 
carried the F10-89-4 determinant, but that not all F10-89-4-bearing molecules carry 
F8-11-13. 
Discussion 
The  data  presented  in  this  paper  clearly  indicate  that  the  LC  "antigen"  or 
"molecule" should not be considered as a  single, discrete entity, but as a  family of 
structurally  related  molecules with  possibly different  functions.  We  show  that,  in 
addition to the antigenic determinant common to all LC molecules and  previously 
defined  by  the  monoclonal  antibody  F10-89-4  (4),  the  LC  molecule  of some-- 
predominantly  B--lymphocytes express an  additional  determinant  defined by the 
monoclonal antibody F8-11- ! 3. This selective expression of a serologically identifiable 762  B-SPECIFIC  DETERMINANT  OF  HUMAN  LEUKOCYTE  COMMON  ANTIGEN 
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FIo. 6.  Cross-inhibition studies using affinity-column-purified  and -depleted spleen extracts. In- 
hibition studies were carried out with: A, F8-11-13  antibody; B, the monoclonal antibody F10-89-4 
directed against the deteminant common to all LC molecules (4); and C, an irrelevant monoclonal 
antibody, F10-44-2 (18), reacting with another antigen in the extract of spleen. The inhibiting 
material consisted of Brij 96 extract of spleen, A; spleen extract after passage through the F8-11-13 
affinity column, m; purified F8-11-13  antigen, O; and spleen extract after passage through the F 10- 
89-4 column, ~  . Purified F10-89-4  antigen was not used as it could not be eluted from the column 
without denaturation. The purified F8-11-13 antigen was concentrated threefold relative to the 
starting spleen extract, as it was eluted from the column in one-third the volume of spleen extract 
applied. 
conformational or  other  structural change  on  the  LC  molecules of a  functionally 
discrete  lymphocyte population suggests  that  the  conformational change  detected 
might  be  of  functional  significance.  For  this  reason,  when  considering  possible 
functions for the LC molecule, one should not think exclusively of a  single function 
likely to be relevant to all LC-bearing leukocytes, but should consider the possibility 
that the LC molecule of B lymphocytes, and, by inference, that of the other different 
LC-bearing leukocyte populations, might be different. Whether or not the antigenic 
determinant common to the LC molecules of all leukocyte populations (detected by 
the F10-89-4 antibody [4])  is of functional importance, either in its own right or in 
relation to the more restricted determinant described here, is a matter for speculation. 
The elucidation of the structural basis for the conformational difference detected in 
the LC molecule from B lymphocytes will be very interesting. One possibility is that 
the  polypeptide chains of all the  LC  molecules are  identical and coded  for by the 
same  gene,  and  that  the  differences  that  arise  are  secondary to  differences  in  the 
number, size, and/or composition of the carbohydrate side chains. These carbohydrate ROSEMARIE DALCHAU AND JOHN W.  FABRE  763 
differences could form new antigenic determinants themselves or lead to alterations 
in  the  folding of the polypeptide chain.  It is  interesting  that  differences have been 
noted  in  the carbohydrate composition of the rat  Thy-1  molecule when  brain  and 
thymus Thy-1 were compared (19), but serologically identifiable differences between 
brain  and  thymic Thy-1  have  not  been  found.  In  any case,  if this  explanation  is 
correct, our data suggest that cellular differentiation and functional specialization can 
result  not  only as a  result  of the expression or not  of a  particular  molecule, but  in 
addition  can  be  a  result  of  secondary  alterations  in  different  cells  of  the  same 
polypeptide chain. 
However, other possibilities exist, such as gene duplication from an ancestral gene 
giving rise to a variety of different but related structural genes in a manner analogous 
to that seen with the K  and D region genes of the H-2 complex, and each gene coding 
for the LC polypeptide chain in a different population of leukocytes. It is also possible 
that  the  LC molecule from B  lymphocytes has a  longer polypeptide chain  and  the 
new determinant could be located on this extra chain.  Various genetic mechanisms 
could be invoked for this such as differences in splicing of essentially the same gene 
(20)  or else separate but related genes with different numbers of domains, as occurs 
with the pt and y chains of immunoglobulin (21). 
It is unlikely that our data could be a result of masking of the FS-11-13 determinant 
on the F8-11-13-negative leukocyte populations. For example, the possibility that the 
FS-11-13  determinant  is masked by other molecules on the membranes of F8-11-13- 
negative cells is excluded  by the biochemical  data.  With  the  LC  molecules free in 
solution, the F8-11-13 affinity columns interacted with only the high molecular weight 
(215,000)  component (Fig. 5). In the rat (2) and mouse (3), it is the LC molecule from 
B lymphocytes that has the highest  molecular weight, so the selective interaction of 
the F8-11-13  antibody on the one hand  predominantly with  B  lymphocytes and on 
the other with  the high molecular weight component of the LC molecules makes a 
coherent picture.  Masking of the FS-I 1-13 determinant  by carbohydrate side chains 
on  the  LC  molecule  itself is  also  unlikely.  Of all  the  LC  molecules,  those  from  B 
lymphocytes have the  highest  apparent  molecular weight  on  SDS-PAGE,  and  are 
therefore the ones that would be most heavily glycosylated. The absence of the FS-11- 
13 determinant on the less heavily glycosylated LC molecules is the reverse of what 
one would expect if glycosylation were a  likely cause of masking. 
The Ly-1 (22)  and Ly-5 (23)  lymphocyte alloantigen systems in the rat and mouse, 
respectively, have recently been shown  to be allodeterminants  on the  LC molecule 
(24,  25). There has been uncertainty as to whether or not these allodeterminants are 
specific to T  lymphocytes, or are only apparently so, because of the use of lympho- 
cytotoxicity as the indicator system (24).  Certainly, the Ly-5 alloantigen of the mouse 
has now clearly been shown to be present on both T  and B lymphocytes (26), but our 
data raise the possibility of T  or B  lymphocyte specific allodeterminants  on the LC 
molecule. 
The finding that the F8-11-13 and F 10-89-4 monoclonal antibodies, which interact 
with very different populations of leukocytes, are in fact detecting different determi- 
nants on the same molecule was unexpected. This result strongly demonstrates that 
it is essential, when comparing monoclonal antibodies,  to think of the targets at the 
determinant rather than the molecular level. In the longer term, it will be interesting 
to see if this phenomenon  of determinant  differences (of possible functional  signifi- 764  B-SPECIFIC  DETERMINANT OF HUMAN LEUKOCYTE COMMON ANTIGEN 
cance) on the same or similar molecules in different cell types is peculiar to the LC 
molecule or is also found with other membrane molecules. 
Summary 
Initial  studies  with  the  monoclonal  antibody  F8-11-13  described  in  this  paper 
showed  that  it  reacted  strongly  with  B  lymphocytes,  did  not  react  at  all  with 
granulocytes, and reacted only weakly with a small subpopulation of thymocytes and 
peripheral  T  lymphocytes. This  picture  was entirely  different  from  that  seen  with 
monoclonal antibodies to the leukocyte common (LC) antigen, where 100% of all the 
above-mentioned  leukocyte  populations  were  positive.  Biochemical  studies  using 
detergent solubilized membranes labeled with aH at  the sialic acid residues showed 
that  the molecule bearing the F8-11-13 determinant  was a  glycoprotein of 215,000 
mol wt, and that the peak depleted by F8-11-13 monoclonal antibody affinity columns 
corresponded to the high molecular weight region of a  broad peak previously shown 
to  be  completely  depleted  by  monoclonal  antibody  (F10-89-4)  affinity  columns 
directed  at  the LC antigen.  Proof that  the F8-11-13 determinant  was expressed  on 
some LO molecules was established by cross-inhibition studies with affinity-column- 
purified and depleted material. This finding of a serologically identifiable conforma- 
tional  or  other  structural  change  selectively  expressed  on  the  LC  molecule  of a 
functionally discrete population of lymphocytes has interesting implications for the 
structure  and  function  of the  LC  molecule,  and  might  be  relevant  to  functional 
considerations of other membrane molecules. 
Received  for publication 22 August 1980. 
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